Building a Sustainable Recovery from COVID-19 in Asia and the Pacific
Since the beginning of the pandemic at the start of 2020, ADB has committed more than $17.5 billion to help its developing member countries address the impacts of COVID-19 and address vaccination needs, and has mobilized a further $12.5 billion in cofinancing from partners.
As the world kickstarts a sustainable recovery from COVID-19, ADB is delivering comprehensive support to meet Asia and the Pacific’s vaccine needs.
Through a $9 billion Asia Pacific Vaccine Access Facility, or APVAX, announced in December 2020, ADB is providing funding for vaccine procurement, logistics, and distribution.
